Who are GRT6005's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trintellix, Dexamethasone and ondansetron, Venlafaxine XR + Mirtazapine, Dexamethasone + Ondansetron, Sodium Bicarbonate Powder and ondansetron, Aprepitant plus Ondansetron.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/grt6005.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

GRT6005 — Competitive Intelligence Brief

GRT6005 (GRT6005) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: serotonin receptor antagonist. Area: Gastrointestinal.

phase 2 serotonin receptor antagonist 5-HT3 receptor Gastrointestinal Small molecule Live · refreshed every 30 min

Target snapshot

GRT6005 (GRT6005) — Tris Pharma, Inc.. GRT6005 is a small molecule drug that targets the serotonin receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GRT6005 TARGET	GRT6005	Tris Pharma, Inc.	phase 2	serotonin receptor antagonist	5-HT3 receptor
Trintellix	vortioxetine	Takeda	marketed	Serotonin modulator and stimulator (SMS); SSRI-like agent	Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor	2013-01-01
Dexamethasone and ondansetron	Dexamethasone and ondansetron	Yeditepe University Hospital	marketed	Corticosteroid + 5-HT3 receptor antagonist combination	Glucocorticoid receptor (dexamethasone); 5-HT3 receptor (ondansetron)
Venlafaxine XR + Mirtazapine	Venlafaxine XR + Mirtazapine	National Institute of Mental Health (NIMH)	marketed	Antidepressant combination (SNRI + NaSSA)	Serotonin transporter, norepinephrine transporter, alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors
Dexamethasone + Ondansetron	Dexamethasone + Ondansetron	University of Catania	marketed	Corticosteroid + 5-HT3 antagonist combination	Glucocorticoid receptor; 5-HT3 receptor
Sodium Bicarbonate Powder and ondansetron	Sodium Bicarbonate Powder and ondansetron	Aya Sabry Mohamed Mohamed	marketed	Antacid and antiemetic combination	5-HT3 receptor (ondansetron); non-specific acid neutralization (sodium bicarbonate)
Aprepitant plus Ondansetron	Aprepitant plus Ondansetron	University of Pittsburgh	marketed	NK1 receptor antagonist + 5-HT3 receptor antagonist combination	NK1 receptor (aprepitant); 5-HT3 receptor (ondansetron)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (serotonin receptor antagonist class)

Serenity Pharmaceuticals, Inc. · 1 drug in this class
Tris Pharma, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GRT6005 — Competitive Intelligence Brief. https://druglandscape.com/ci/grt6005. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab